Global Research & Development

Astellas Pharma Global Development Europe (APGD-EU) stands at the leading edge of science and technology. Our R&D strategy focuses on the acceleration and commercialisation of new drugs by concentrating resources on promising projects within clearly defined therapeutic areas.

APGD-EU assumes global responsibility for R&D development in:

• Urology
• Diabetes/Metabolism/Kidney/Cardiovascular Disease
• Pain Management

APGD-EU also supports global R&D development efforts in the therapeutic areas (TAs) of:

• Transplantation
• Inflammation/Immunology (including Gastrointestinal Diseases)
• CNS
• Infectious Diseases
• Oncology

Worldwide, Astellas has 30 major projects in Phase 3 or pending approval, and more than 50 projects in early-phase clinical development.

We aim to be category leaders within focused therapeutic areas in order to improve the quality of life for patients, their families, and the caregivers who serve them.

Drug discovery and development process